Tags : study

Clinical Trials

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to

Shots: The companies collaborated to evaluate Mirati’s adagrasib (KRASG12C inhibitor) + Sanofi’s SAR442720 (SHP2 inhibitor) in P-I/II dose-escalation & expansion study in patients with previously-treated NSCLC & KRASG12C mutations Adagrasib & SAR442720 demonstrated an anti-tumor activity in pre-clinical models & both have complementary MoA Sanofi will be responsible for sponsoring & operating the P-I/II study & both […]Read More

Biosimilars Clinical Trials

Tanvex Presents Results of TX05 (biosimilar, trastuzumab) in P-III Study

Shots: The P-III study evaluates TX05 (biosimilar, trastuzumab) vs Herceptin in 809 patients with HER2-positive early-stage breast cancer The results showed that the proportions of patients that meet pCR criteria for equivalence were highly similar b/w TX05 (48.8%) and TRA (45.3%) cohorts; ORR (84.3%) & (85.0%); CR; PR and stable disease were also highly similar, […]Read More